May 2022 "Published: May 10, 2022 To accelerate clinical development of its best-in-class and first-in-class

April 2022 "By Sophie Bradley | Apr 12, 2022 Summary Sophie Bradley, Translational Sciences Associate

May 2022 "Seoul, South Korea, 28 April 2022 – GPCR therapeutics , Inc., a venture-backed clinical stage

April 2022 "SAN DIEGO, April 12, 2022 — Crinetics Pharmaceuticals , Inc. underwritten follow-on offering of 5,625,563 shares of its common stock at a price to the public of $22.22 The offering is expected to close on or about April 18, 2022, subject to the satisfaction of customary

April 2022 John Streicher talks about his work on terpenes found in cannabis as these may be a novel

April 2022 Trevena Announces Receipt of First $15 million Tranche in Connection with its $40 million ex-US Royalty-Based Financing with R-Bridge Healthcare Fund " CHESTERBROOK, Pa., April 18, 2022 - Trevena

April 2022 Applying Allosteric Modulator Pharmacology to Treat Dyskinesia and Other Movement Disorders

April 2022 Trevena Receives up to $40M in OLINVYK ex-US Royalty-Based Financing from R-Bridge Healthcare Fund, an affiliate of CBC Group " CHESTERBROOK, Pa., March 31, 2022 -- Trevena , Inc.

April 2022 "By Cliona MacSweeney | Apr 20, 2022 Cliona MacSweeney, a project director in our Translational

April 2022 Read more at the source #DrGPCR #GPCR #IndustryNews

April 2022 Sosei Heptares Confirms Senior Leadership Changes to Drive the Company Through the Next Stage ‘Venture-like’ capital allocation approach to focus pipeline development through to Phase 1b/2a appointed President of Heptares Therapeutics Ltd., and Head of UK R&D Tokyo, Japan and Cambridge, UK, 24 March 2022 – Sosei Group Corporation (“the Company”; TSE: 4565) today confirms that a series of Executive

April 2022 Design Pharmaceuticals Closes $5 Million Pre-series A Round to Accelerate Commercialization of Ultrahigh Throughput Drug Discovery Platform " April 12, 2022 07:00 AM Eastern Daylight Time CAMBRIDGE

April 2022 Addex Expands Pipeline With Selective M4 Positive Allosteric Modulator Program For The Treatment Modulator Screening Platform Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, April 6, 2022

March 2022 Inversago Pharma Announces Dosing of First Participant with Metabolic Syndrome in Phase 1B Clinical Trial " MONTREAL (CANADA) – March 15, 2022 – Inversago Pharma Inc. This 28-day trial will test the pharmacokinetics and safety profile of Inversago’s lead molecule, INV -202, on a targeted population with metabolic syndrome.

March 2022 "Congratulations to Richard J. Law , our newly named Chief Business Officer.

March 2022 " Explicyte grants Domain Therapeutics exclusivity on data related to GPCR implicated in Strasbourg and Bordeaux, France, March 10, 2022 – Domain Therapeutics , a biopharmaceutical company specializing

March 2022 Crinetics Pharmaceuticals Expands Executive Team With Appointment Of James Hassard As Chief Commercial Officer "SAN DIEGO – March 1, 2022 – Crinetics Pharmaceuticals , Inc.

February 2022 Read more at the source #DrGPCR #GPCR #IndustryNews

February 2022 Trevena Announces Submission of New Drug Application in China for OLINVYK® by its Partner commercialization milestones, as well as a 10% royalty on net sales in China CHESTERBROOK, Pa., Jan. 27 , 2022 A biopharmaceutical company focused on the development and commercialization of novel medicines

January 2022 "We are an experienced, innovative, global team on a bold mission to improve health by

January 2022 "The Neurocrine Biosciences story puts into words what makes the work and people at Neurocrine

Median ligand RMSD values for top-scored poses were 1.2 Å and 2.0 Å for self-docking and StateMatch/FunctionMatch

Expected final online publication date for the Annual Review of Biophysics , Volume 51 is May 2022.

Almost 20 years ago, GPCR activity was shown to be regulated by membrane potential in vitro, but whether

This IL-6 release could be blocked by a Gαq inhibitor (YM-254890), an IKK complex inhibitor (IKK-16),

heterodimerises with multiple G protein-coupled receptors (GPCRs), including dopamine D1 and D2, serotonin 2C

compound's antagonist behavior on D1R (IC50 42.1 ± 0.35 μM) and agonist effect on D2LR and D4R (EC50 22.4

We find that the enzymes involved in ascaroside pheromone biosynthesis, ACOX-1.1, ACOX-1.2, and DAF-22